Pfizer Inc.
Pfizer Research Technology Center (RTC)
620 Memorial Drive
Cambridge
Massachusetts
02139
United States
Tel: 617-551-3000
Fax: 617-551-3111
Website: http://www.pfizer.com/
About Pfizer Inc.
The Pfizer Research Technology Center (RTC) in Cambridge, MA houses cutting edge research groups focused on RNAi therapeutics, Systems Biology and Biological Profiling, Regenerative Medicine and Computational Sciences.
Headquartered at the RTC, and comprising research groups in Cambridge and Düsseldorf, the goal of Pfizer RNAi Therapeutics is clear - delivering RNAi therapies to meet our patient needs and in doing so helping Pfizer become a top tier biotherapeutics company.
Pfizer Regenerative Medicine is collaborating with local experts to develop Stem Cell Therapies to treat diseases.
The Systems Biology, Biological Profiling and Computational Sciences groups are using their niche skills and expertise to focus on increasing the effectiveness of the research process through better target selection, reduced attrition and the ability to manipulate and manage data to support the research process.
Without the constraints of a therapeutic area portfolio, RTC colleagues are free to apply cutting-edge techniques and technologies with broad utility across different therapeutic areas.
The RTC is located in one of the richest scientific environments in the world, surrounded by more than 300 biotechnology companies and thousands of scientific innovators in world-leading research hospitals and academic institutions. A key element in the success of the RTC is the growing and dynamic portfolio of partnerships with these innovators, focused on addressing the strategic needs of the site and of Pfizer's research division.
The RTC aims to balance the strength of Pfizer R&D with the nimble feel of a small biotech, and creates an exciting and team-based scientific environment for 150 colleagues, with a wide range of scientific skills and experience. The working environment emphasizes collaboration and cooperation with most scientific questions solved through the work of a cross-disciplinary team. The unique working environment - truly a small biotech with the backing of the largest research budget in the industry - supports the unique science of the site.
For more information, please visit www.pfizercambridge.com
126 articles about Pfizer Inc.
-
Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25
4/11/2024
Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual-only 2024 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April 25, 2024.
-
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
4/9/2024
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO ® in Adults Aged 18 to 59 at Increased Risk for RSV Disease.
-
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference - March 5, 2024
3/5/2024
Pfizer Inc. (NYSE: PFE) invites investors and the general public listen to a webcast of a discussion with Mikael Dolsten, Chief Scientific Officer & President, Pfizer Research and Development, at the Leerink Partners Global Biopharma Conference 2024 on Tuesday, March 12, 2024 at 8:00 a.m. Eastern Daylight Time.
-
Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO® for RSV in Older Adults
2/29/2024
Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO ® for RSV in Older Adults.
-
Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance
1/30/2024
Pfizer Inc. (NYSE: PFE) reported financial results for fourth quarter and full-year 2023 and reaffirmed its 2024 financial guidance(5) provided on December 13, 2023.
-
TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
1/9/2024
Genmab A/S (Nasdaq: GMAB) and Pfizer, Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) seeking to convert the accelerated approval of TIVDAK® (tisotumab vedotin-tftv) to full approval, for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after first-line therapy.
-
European Commission Approves Pfizer’s TALZENNA® in Combination with XTANDI® for Adult Patients with Metastatic Castration-Resistant Prostate Cancer
1/8/2024
European Commission Approves Pfizer’s TALZENNA ® in Combination with XTANDI ® for Adult Patients with Metastatic Castration-Resistant Prostate Cancer.
-
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference - November 21, 2023
11/21/2023
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with David Denton, Chief Financial Officer, Executive Vice President, at the Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023 at 10:50 a.m. EST.
-
Serina Therapeutics Announces POZ Polymer Technology License Agreement with Pfizer
11/17/2023
Serina Therapeutics, Inc. today announced Serina has entered into a License Agreement under which Pfizer Inc. will license, on a non-exclusive basis, Serina’s POZ polymer technology.
-
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference - September 19, 2023
9/19/2023
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 2023 Cantor Global Healthcare Conference on Tuesday, September 26, 2023 at 3:30 p.m. EDT.
-
Pfizer Announces Executive Leadership to Advance Oncology Research and Development Strategy
7/27/2023
Pfizer Inc. (NYSE: PFE) today announced changes to its executive leadership team to further advance its aspirations to discover and develop new medicines and vaccines, with an emphasis on oncology.
-
Riparian Pharmaceuticals Announces Agreements with Pfizer for Novel Cardiovascular Programs
7/19/2023
Riparian Pharmaceuticals today announced it has entered into an exclusive license agreement and research agreement with Pfizer.
-
Carrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant Combination
7/6/2023
Carrick Therapeutics today announced a clinical trial collaboration and supply agreement with Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE).
-
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference - June 6, 2023
6/6/2023
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with William Pao, Chief Development Officer, Executive Vice President, at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13, 2023 at 8:00 a.m. Pacific Daylight Time.
-
Thermo Fisher Scientific & Pfizer Partner to Expand Localized Access to Next-Generation Sequencing-Based Testing for Cancer Patients in International Markets
5/9/2023
Pfizer and Thermo Fisher Scientific Inc. (NYSE: TMO) today announced they have entered into a collaboration agreement to help increase local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in more than 30 countries across Latin America, Africa, the Middle East and Asia where advanced genomic testing has previously been limited or unavailable.
-
Pfizer Reports First-Quarter 2023 Results
5/2/2023
Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2023 and reaffirmed full-year 2023 financial guidance.
-
Pfizer Invites Shareholders to Attend Virtual-Only 2023 Annual Meeting of Shareholders on April 27
4/13/2023
Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual-only 2023 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April 27, 2023.
-
Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval
3/10/2023
Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant),.
-
Pfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adults
2/28/2023
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that available data is adequate to support the safety and effectiveness of its respiratory syncytial virus (RSV) bivalent vaccine candidate PF-06928316 or RSVpreF.
-
Pfizer’s Elranatamab Receives FDA and EMA Filing Acceptance
2/22/2023
Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the company’s Biologics License Application (BLA) for elranatamab, an investigational B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody (BsAb).